Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
UVIC INDUSTRY PARTNERSHIPS INC. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 4 distinct examiners and 4 distinct art units, giving the portfolio a fully dispersed examination structure.
GUSTILO, ESTELLA M is the busiest examiner, with 1 pending matter. The data does not show a dominant examiner concentration, so prosecution oversight should emphasize coordination across separate applications and technical examination settings.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
| WHITE, DENNIS MICHAEL | 1 | 58.0% | +48.4% |
| GRABER, JAMES J | 1 | 46.5% | +57.6% |
| PATTERSON, SARAH COOPER | 1 | 56.1% | +51.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286045 | MODIFIED GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) AND CHIMERIC CYTOKINE RECEPTORS BINDING SAME | GUSTILO, ESTELLA M | — |
| 18360442 | MICROFLUIDIC DEVICE WITH INTEGRATED MAGNETS FOR BIOMARKER DETECTION AND MANIPULATION | WHITE, DENNIS MICHAEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17767687 | Chimeric Cytokine Receptors | GRABER, JAMES J | 26d |
| 17642089 | ANTI-ONCOLYTIC VIRUS ANTIGEN ANTIBODIES AND METHODS OF USING SAME | PATTERSON, SARAH COOPER | 46d |
| 18286045 | MODIFIED GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) AND CHIMERIC CYTOKINE RECEPTORS BINDING SAME | GUSTILO, ESTELLA M | — |
| 18360442 | MICROFLUIDIC DEVICE WITH INTEGRATED MAGNETS FOR BIOMARKER DETECTION AND MANIPULATION | WHITE, DENNIS MICHAEL | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1758 | 1 |
| 1631 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18286045 | MODIFIED GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) AND CHIMERIC CYTOKINE RECEPTORS BINDING SAME | GUSTILO, ESTELLA M | 1646 | §102§103§112Other | Final Rejection | — | Pending | Oct 06, 2023 |
| 18360442 | MICROFLUIDIC DEVICE WITH INTEGRATED MAGNETS FOR BIOMARKER DETECTION AND MANIPULATION | WHITE, DENNIS MICHAEL | 1758 | §102§103 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 17767687 | Chimeric Cytokine Receptors | GRABER, JAMES J | 1631 | §103DP | Final Rejection | 26d | Pending | Apr 08, 2022 |
| 17642089 | ANTI-ONCOLYTIC VIRUS ANTIGEN ANTIBODIES AND METHODS OF USING SAME | PATTERSON, SARAH COOPER | 1675 | §112Other | Final Rejection | 46d | Pending | Mar 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUVIC INDUSTRY PARTNERSHIPS INC. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Estella M Gustilo has the most, with 1 of UVIC INDUSTRY PARTNERSHIPS INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
